文献速递心境障碍会诊联络精神医学

胰高血糖素样肽-1受体激动剂作为双相障碍新兴治疗:临床前与临床证据的叙述性综述

Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence.
PubMed 文献 · Mol Psychiatry · 2025-09-13

本叙述性综述综合临床前、临床及真实世界证据,评估胰高血糖素样肽-1受体激动剂(GLP-1RAs)在双相障碍(BD)中的治疗潜力。GLP-1RAs通过调节神经传递、减轻神经炎症与氧化应激、增强线粒体与神经营养功能、改善胰岛素敏感性及HPA轴调控发挥作用,初步显示对抑郁、焦虑、躁狂、认知功能障碍、体重增加及物质使用障碍等核心病理域和常见共病有益。人类数据尤其BD人群仍有限,但证据提示辅助治疗可能获益,需设计良好的对照试验确认疗效与安全性。

要点

  • GLP-1RAs通过多靶点神经生物学机制可能改善BD核心症状与代谢共病。
  • 现有BD人群证据有限,初步提示对代谢或认知脆弱个体有辅助获益潜力。
  • 需设计良好的对照试验确认疗效、安全性、最佳亚组及长期结局。

核心结论

  • GLP-1RAs因其多效作用和已知安全性,是双相障碍药物重定位的有力候选。
  • 初步证据提示GLP-1RAs在BD中可能具有辅助治疗获益,尤其对代谢或认知脆弱个体。

研究设计与样本

  • 叙述性综述,综合临床前、临床及真实世界证据评估GLP-1RAs在BD中的治疗潜力。

主要发现

  • GLP-1RAs调节神经传递、减轻神经炎症与氧化应激、增强线粒体与神经营养功能、改善胰岛素敏感性及HPA轴调控。
  • 初步发现提示GLP-1RAs对抑郁、焦虑、躁狂、认知功能障碍、体重增加及物质使用障碍等核心病理域和常见共病有益。
  • 人类数据尤其BD人群仍有限,但证据指向潜在辅助获益。

临床怎么用

  • 在BD患者中,尤其合并代谢或认知脆弱时,可考虑GLP-1RAs作为辅助治疗选项。
  • 当前证据尚不足以支持常规处方,需结合个体情况并等待对照试验结果。

局限性

  • 人类数据尤其BD人群证据有限。
  • 需设计良好的对照试验确认疗效与安全性、识别最佳亚组及评估长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bipolar disorder (BD) is a chronic and disabling psychiatric illness characterized by complex pathophysiological mechanisms. Traditional treatments often fail to address these multidimensional processes, highlighting the need for novel therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for metabolic disorders, have emerged as promising candidates for a range of neuropsychiatric conditions due to their broad neurobiological effects. This narrative review synthesizes preclinical, clinical, and real-world evidence evaluating the therapeutic potential of GLP-1RAs in BD. These agents modulate neurotransmission, reduce neuroinflammation and oxidative stress, enhance mitochondrial and neurotrophic function, and improve insulin sensitivity and hypothalamic-pituitary-adrenal (HPA) axis regulation. These mechanisms are implicated in the neurobiology of BD, and preliminary findings suggest benefits across core psychopathological domains and common comorbidities, including depression, anxiety, mania, cognitive dysfunction, weight gain, and substance use disorders. While human data-particularly in BD populations-remain limited, evidence points to potential adjunctive benefits, especially in individuals with metabolic or cognitive vulnerabilities. Given their pleiotropic actions and established safety profile, GLP-1RAs represent compelling candidates for drug repurposing in BD. Well-powered, controlled trials are needed to confirm efficacy and safety, identify optimal subgroups, and evaluate long-term outcomes.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Llach CD, Badulescu S, Tabassum A, et al. Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence. Mol Psychiatry. 2025. PMID: 40940560. doi:10.1038/s41380-025-03261-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。